A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
MEDINCELL S.A. operates in the Biotechnology industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 29M | 29M | - | - | - | - |
| Net Income | -21M | -21M | -27M | -35M | -26M | -22M |
| EPS | $-0.70 | $-0.70 | $-0.95 | $-1.38 | $-1.05 | $-1.01 |
| Free Cash Flow | 21M | 21M | -13M | -23M | -24M | -15M |
| ROIC | -9.5% | -556.8% | -1624.7% | -64.7% | -42.5% | -422.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | - | - | - | - | 4.48 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -12M | -12M | -23M | -26M | -25M | -18M |
| Operating Margin | -42.6% | -42.6% | - | - | - | - |
| ROE | 0.0% | - | - | - | - | -208.0% |
| Shares Outstanding | 30M | 30M | 28M | 25M | 25M | 22M |
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | 29M | 29M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | -23M | -25M | -30M | -23M | -28M | -28M |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -18M | -25M | -26M | -23M | -12M | -12M |
| Op. Margin | N/A | N/A | N/A | N/A | -42.6% | -42.6% |
| Net Income | -22M | -26M | -35M | -27M | -21M | -21M |
| Net Margin | N/A | N/A | N/A | N/A | -72.5% | -72.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/M | -42.5% | -64.7% | N/M | N/M | -9.5% |
| ROE | -208.0% | N/A | N/A | N/A | N/A | 0.0% |
| ROA | -29.8% | -42.9% | -88.5% | -75.4% | -29.3% | -20.4% |
| Cash Flow | ||||||
| Op. Cash Flow | -14M | -22M | -23M | -13M | 22M | 22M |
| Free Cash Flow | -15M | -24M | -23M | -13M | 21M | 21M |
| Owner Earnings | -18M | -27M | -27M | -18M | 16M | 16M |
| CapEx | 761K | 1.7M | 625K | 350K | 846K | 846K |
| Maint. CapEx | 1.6M | 1.6M | 1.8M | 1.9M | 2.3M | 2.3M |
| Growth CapEx | 0 | 113K | 0 | 0 | 0 | 0 |
| D&A | 1.6M | 1.6M | 1.8M | 1.9M | 2.3M | 2.3M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 3.8% | 3.8% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 332K | 202K | 333K | 27K | 105K | 105K |
| Buyback Yield | 0.1% | 0.1% | 0.2% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | 1.8M | 2.5M | 2.5M | 3.0M | 3.4M | 3.4M |
| Debt Repayment | 11M | 2.4M | 26M | 9.5M | 4.6M | 4.6M |
| Balance Sheet | ||||||
| Net Debt | -7.3M | -5.5M | 8.8M | 45M | 20M | -67M |
| Cash & Equiv. | 56M | 26M | 7.0M | 21M | 67M | 67M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 4.48 | N/A | N/A | N/A | N/A | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | 11M | -14M | -46M | -44M | -19M | -19M |
| Total Assets | 75M | 47M | 32M | 40M | 102M | 102M |
| Total Liabilities | 64M | N/A | N/A | N/A | N/A | N/A |
| Intangibles | 1.8M | N/A | N/A | 2.6M | 3.0M | 3.0M |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A | N/A |
| Working Capital | 50M | -4.4M | -41M | 12M | 57M | 57M |
| Current Assets | 66M | 36M | 21M | 29M | 91M | 91M |
| Current Liabilities | 16M | 40M | 62M | 18M | 34M | 34M |
| Per Share Data | ||||||
| EPS | -1.01 | -1.05 | -1.38 | -0.95 | -0.70 | -0.70 |
| Owner EPS | -0.80 | -1.07 | -1.07 | -0.62 | 0.55 | 0.55 |
| Book Value | 0.49 | -0.57 | -1.82 | -1.55 | -0.62 | -0.62 |
| Cash Flow/Share | -0.65 | -0.91 | -0.90 | -0.45 | 0.74 | -0.63 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 22.1M | 24.8M | 25.2M | 28.5M | 29.7M | 29.7M |
| Valuation | ||||||
| P/E Ratio | -10.5 | -6.7 | -5.8 | -18.9 | -41.9 | -33.1 |
| P/FCF | N/A | N/A | N/A | N/A | 41.2 | 32.6 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 21.9 | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | 30.4 | 24.0 |
| FCF Yield | -6.4% | -13.9% | -11.7% | -2.6% | 2.4% | 3.1% |
| Market Cap | 236M | 174M | 201M | 512M | 874M | 691M |
| Avg. Price | 12.21 | 6.70 | 7.84 | 14.84 | 22.54 | 23.22 |
| Year-End Price | 10.68 | 7.01 | 7.96 | 18.00 | 29.39 | 23.22 |
MEDINCELL S.A. passes 0 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 32.6x vs a median of 41.2x.
MEDINCELL S.A. (MEDCL-PA) has a 5-year average return on invested capital (ROIC) of -53.6%. This is below average and may indicate limited pricing power.
MEDINCELL S.A. (MEDCL-PA) has a market capitalization of $691M. It is classified as a small-cap stock.
MEDINCELL S.A. (MEDCL-PA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.02%.
MEDINCELL S.A. (MEDCL-PA) operates in the Biotechnology industry, within the Healthcare sector.
MEDINCELL S.A. (MEDCL-PA) reported annual revenue of $29 million in its most recent fiscal year, based on SEC EDGAR filings.
MEDINCELL S.A. (MEDCL-PA) has a net profit margin of -72.5%. The company is currently unprofitable.
MEDINCELL S.A. (MEDCL-PA) generated $21 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
MEDINCELL S.A. (MEDCL-PA) reported earnings per share (EPS) of $-0.70 in its most recent fiscal year.
The Ledger Terminal provides 5 years of financial data for MEDINCELL S.A. (MEDCL-PA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
MEDINCELL S.A. (MEDCL-PA) has a book value per share of $-0.62, based on its most recent annual SEC filing.